GYRE GYRE THERAPEUTICS
Health Care · Russell 2000
Next earnings: not announced yet
What 5 analyst firms say about GYRE THERAPEUTICS: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
4 rated views · 5 analyst/firm records · 5 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Fewer than 5 analysts in the last 6 months (4)
- Russell 2000 · Safest consensus · 6MNot scored · Fewer than 5 analysts in the last 6 months (4)
Recent analyst activity · last 90 days
Our tracked history has 2 reports on GYRE from 2 analyst firms in the last 90 days (5 firms in the past year).
Comparing each firm's latest target with its previous one: 1 has its first observed target in the past year.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| H.C. Wainwright | Matthew Keller | Buy | 7 Aug 2026 | 18.00 USD |
| Jefferies | Roger Song | Buy | 5 Mar 2026 | 18.00 USD |
| Noble Capital Markets | Robert Leboyer | Buy | 10 Aug 2026 | 20.00 USD |
| Weiss Ratings | Unnamed analyst | — | 7 Aug 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 6 Oct 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 08:12 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.